Analysts Set Expectations for Palisade Bio Q1 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Palisade Bio in a research note issued to investors on Thursday, March 26th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. HC Wainwright also issued estimates for Palisade Bio’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.12) EPS.

Several other equities analysts have also recently commented on the stock. Piper Sandler began coverage on shares of Palisade Bio in a research report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target for the company. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Stifel Nicolaus assumed coverage on Palisade Bio in a research note on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price for the company. Finally, B. Riley Financial assumed coverage on Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Palisade Bio Stock Performance

PALI stock opened at $2.00 on Monday. The business’s fifty day moving average price is $1.78 and its 200 day moving average price is $1.76. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.64. The company has a market capitalization of $331.76 million, a PE ratio of -0.94 and a beta of 1.53.

Institutional Trading of Palisade Bio

A number of large investors have recently made changes to their positions in PALI. Perceptive Advisors LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $28,318,000. Commodore Capital LP acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $26,896,000. Janus Henderson Group PLC purchased a new stake in shares of Palisade Bio during the fourth quarter worth approximately $24,822,000. RA Capital Management L.P. purchased a new stake in shares of Palisade Bio during the fourth quarter worth approximately $16,742,000. Finally, Eversept Partners LP acquired a new stake in shares of Palisade Bio during the fourth quarter worth $12,670,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Palisade Bio News Roundup

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $7.00 price target — a material upside vs. the current share price that can attract buyer interest and improve sentiment. Palisade Bio (NASDAQ:PALI) Research Coverage Started at HC Wainwright
• Neutral Sentiment: HC Wainwright published detailed EPS forecasts: quarterly losses in the range of roughly ($0.01)–($0.03) through FY2027 and an FY2027 EPS forecast of about ($0.12). These projected small per-quarter losses suggest the analyst model anticipates limited near-term burn per share, but results will hinge on clinical and business execution. MarketBeat PALI coverage summary
• Negative Sentiment: Palisade remains unprofitable; continued negative EPS implies potential future financing/dilution and exposes the stock to clinical and regulatory binary risks common to biotech names — these are key downside factors for investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.